How To Choose An Immunoassay Platform For Cell & Gene Therapy Bioanalysis
The key factors to automating assay development to get results quicker Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spi...
Executive Abstract
Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spinal muscular atrophy (SMA) and the healthy pipeline of new treatments in development, the gene therapy landscape is highly competitive and timelines are compressed to bring new therapies to market.
In addition, the focus on patient safety creates very specialized demands on bioanalytical methods utilized for vector and host cell protein quantitation, and for immunogenicity monitoring. Since immunoassays are traditionally time consuming and laborious, choosing the right immunoassay platform to meet the demands of data quality and assay speed significantly affects development timelines and deadlines for regulatory submissions.
These are key factors to consider when choosing an immunoassay platform for cell and gene therapy bioanalysis in preclinical, clinical, and bioprocessing stages of development.
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
Guide
Chronic Obstructive Pulmonary Disease- Pipeline Analysis 2018
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. There are total 141 m...
White Paper
Increasing Patient Engagement and Helping Clinical Trials Reach Full Potential with the Clinical Research as a Care Option Model
Only 3% of people with cancer participate in clinical trials. CRAACO seamlessly integrates clinical research with medical care, so more patients and physicians...
White Paper
How to Use Risk-Based Monitoring and Clinical CAPA to Ensure Compliance
If your company is a sponsor or a CRO that conducts clinical research for a sponsor, how effective are your risk management and clinical CAPA processes? Are you...